12/4
01:01 pm
hoth
Hoth Therapeutics (NASDAQ:HOTH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Low
Report
Hoth Therapeutics (NASDAQ:HOTH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
12/3
02:00 pm
hoth
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
Low
Report
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
12/1
08:10 am
hoth
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025 [Yahoo! Finance]
Medium
Report
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025 [Yahoo! Finance]
12/1
08:03 am
hoth
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025
Medium
Report
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025
11/20
08:50 am
hoth
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities [Yahoo! Finance]
High
Report
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities [Yahoo! Finance]
11/20
08:13 am
hoth
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities
High
Report
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities
11/17
08:20 am
hoth
Hoth Therapeutics (NASDAQ:HOTH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Medium
Report
Hoth Therapeutics (NASDAQ:HOTH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
10/27
07:49 am
hoth
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
Low
Report
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
12/5
06:03 am
hoth
Form EFFECT Hoth Therapeutics, Inc.
Neutral
Report
Form EFFECT Hoth Therapeutics, Inc.
11/17
06:00 am
hoth
Form S-3 Hoth Therapeutics, Inc.
Low
Report
Form S-3 Hoth Therapeutics, Inc.
11/13
01:03 pm
hoth
Form 424B5 Hoth Therapeutics, Inc.
Low
Report
Form 424B5 Hoth Therapeutics, Inc.
11/12
04:18 pm
hoth
Form 10-Q Hoth Therapeutics, Inc. For: Sep 30
Medium
Report
Form 10-Q Hoth Therapeutics, Inc. For: Sep 30
10/17
04:16 pm
hoth
Form 8-K Hoth Therapeutics, Inc. For: Oct 17
Low
Report
Form 8-K Hoth Therapeutics, Inc. For: Oct 17
9/12
08:15 am
hoth
Form 8-K Hoth Therapeutics, Inc. For: Sep 12
Low
Report
Form 8-K Hoth Therapeutics, Inc. For: Sep 12
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register